Webinar to Address New Approaches to Flexible Biopharmaceutical Manufacturing Capacity
In recent years, dramatic improvements in product titer and yield in manufacturing operations, the development of more potent biopharmaceutical products such as antibody-drug conjugates, and the increased focus on developing products for personalized medicine of small niche markets have driven a demand for smaller, more flexible, and cost-effective manufacturing facility options. These trends, coupled with advancements in single use technologies have revolutionized biopharmaceutical manufacturing.
New facilities, such as the DSM Pharmaceutical Products “biologics plant of the future” in Brisbane, Australia and the Fujifilm Diosynth Biotechnologies new mammalian cell culture facility in Billingham, UK are being designed to utilize primarily single-use technologies for both upstream and downstream operations. These new flexible facilities enable not only the rapid production of clinical trial material but also offer the potential for more efficient commercial manufacturing of monoclonal antibodies and other biopharmaceutical products. To learn more about this exciting new trend in the biopharmaceutical industry, join me on November 19, 2013 for a Business Review webinar entitled “Going beyond flexible single use facility for achieving efficient commercial manufacturing.”
Blog article by: Howard L. Levine